Multiple infliximab biosimilar switches appear to be safe and effective in a real‐world inflammatory bowel disease cohort
United European Gastroenterology Journal · 2023
DOI: 10.1002/ueg2.12357 ↗Kurz gefasst
Fachartikel in der Zeitschrift United European Gastroenterology Journal, 2023. Verfasst von Beatriz Gros und 9 weiteren Autor:innen. Beteiligte Einrichtung: Edinburgh IBD Unit, Western General Hospital, Edinburgh, UK. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Medical Research Council, UK Research and Innovation.
Abstract (Originalsprache)
Background
Switching from originator infliximab (IFX) to biosimilar IFX is effective and safe. However, data on multiple switching are scarce. The Edinburgh inflammatory bowel disease (IBD) unit has undertaken three switch programmes: (1) Remicade to CT‐P13 (2016), (2) CT‐P13 to SB2 (2020), and (3) SB2 to CT‐P13 (2021).
Objective
The primary endpoint of this study was to assess CT‐P13 persistence following switch from SB2. Secondary endpoints included persistence stratified by the number of biosimilar switches (single, double and triple), effectiveness and safety.
Methods
We performed a prospective, observational, cohort study. All adult IBD patients on IFX biosimilar SB2 underwent an elective switch to CT‐P13. Patients were reviewed in a virtual biologic clinic with protocol driven collection of clinical disease activity, C‐reactive protein (CRP), faecal calprotectin (FC), IFX trough/antibody levels, and drug survival.
Results
297 patients (CD n = 196 [66%], ulcerative colitis/inflammatory bowel disease unclassified n = 101, [34%]) were switched (followed‐up: 7.5 months [6.8–8.1]). This was the third, second and first IFX switch for 67/297 (22.5%), 138/297 (46.5%) and 92/297 (31%) of the cohort respectively. 90.6% of patients remained on IFX during follow‐up. The number of switches was not independently associated with IFX persistence after adjusting for confounders. Clinical ( p = 0.77), biochemical (CRP ≤5 mg/ml; p = 0.75) and faecal biomarker (FC
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Edinburgh IBD Unit, Western General Hospital, Edinburgh, UK.
- Department of Gastroenterology and Hepatology, Reina Sofía University Hospital, Córdoba, Spain.
- MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Western General Hospital, Edinburgh, UK.
- Centre for Genomics and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, Western General Hospital, Edinburgh, UK.
- Edinburgh Pharmacy Unit, Western General Hospital, Edinburgh, UK.
- Centre for Inflammation Research, The Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UK.
ORCID-Profile: Beatriz Gros, Nikolas Plevris, Lauranne A A P Derikx
Förderung
- Wellcome Trust
- Medical Research Council
- UK Research and Innovation
Zitieren
APA
Gros, B., Plevris, N., Constantine-Cooke, N., Lyons, M., O'Hare, C., Noble, C., Arnott, I. D., Jones, G. R., Lees, C. W., & Derikx, L. A. A. P. (2023). Multiple infliximab biosimilar switches appear to be safe and effective in a real‐world inflammatory bowel disease cohort. United European Gastroenterology Journal. https://doi.org/10.1002/ueg2.12357
Vancouver
Gros B, Plevris N, Constantine-Cooke N, Lyons M, O'Hare C, Noble C, et al. Multiple infliximab biosimilar switches appear to be safe and effective in a real‐world inflammatory bowel disease cohort. United European Gastroenterology Journal. 2023. doi:10.1002/ueg2.12357
BibTeX
@article{Gros2023,
author = {Gros, Beatriz and Plevris, Nikolas and Constantine-Cooke, Nathan and Lyons, Mathew and O'Hare, Claire and Noble, Colin and Arnott, Ian D and Jones, Gareth-Rhys and Lees, Charlie W and Derikx, Lauranne A A P},
title = {Multiple infliximab biosimilar switches appear to be safe and effective in a real‐world inflammatory bowel disease cohort},
journal = {United European Gastroenterology Journal},
year = {2023},
doi = {10.1002/ueg2.12357}
}
EUVIMED